Synergistic Anticancer Therapy by Ovalbumin Encapsulation‐Enabled Tandem Reactive Oxygen Species Generation. Issue 45 (15th September 2020)

• Record Type: Journal Article
• Authors: Jiang, Shuai; Xiao, Ming; Sun, Wen; Crespy, Daniel; Mailänder, Volker; Peng, Xiaojun; Fan, Jiangli; Landfester, Katharina
• Is Part Of: Angewandte Chemie international edition. Volume 59:Issue 45(2020)
• Page Start: 20008
• Page End: 20016
• Publication Date: 2020-09-15
• Subjects: cisplatin -- Fenton reactions -- hypoxic -- photodynamic therapy -- synergistic; Chemistry -- Periodicals; 540
• DOI: 10.1002/anie.202006649
• Languages: English
• ISSNs: 1433-7851

Abstract

Abstract: The anticancer efficacy of photodynamic therapy (PDT) is limited due to the hypoxic features of solid tumors. We report synergistic PDT/chemotherapy with integrated tandem Fenton reactions mediated by ovalbumin encapsulation for improved in vivo anticancer therapy via an enhanced reactive oxygen species (ROS) generation mechanism. O2 .− produced by the PDT is converted to H2 O2 by superoxide dismutase, followed by the transformation of H2 O2 to the highly toxic . OH via Fenton reactions by Fe 2+ originating from the dissolution of co‐loaded Fe3 O4 nanoparticles. The PDT process further facilitates the endosomal/lysosomal escape of the active agents and enhances their intracellular delivery to the nucleus—even for drug‐resistant cells. Cisplatin generates O2 .− in the presence of nicotinamide adenine dinucleotide phosphate oxidase and thereby improves the treatment efficiency by serving as an additional O2 .− source for production of . OH radicals. Improved anticancer efficiency is achieved under both hypoxic and normoxic conditions. Abstract : Synergistic photodynamic/chemotherapy is reported with integrated tandem Fenton reactions enabled by ovalbumin co‐encapsulation. In vivo anticancer therapy is improved via an enhanced reactive oxygen species (ROS) generation mechanism.